BRNSBarinthus Biotherapeutics plc.同业对比
Barinthus Biotherapeutics plc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRNS本股 | $31M#8 | — | 0.5x#3 | — | -100.0%#9 | -8.8%#5 | — | -116.4%#9 | — | — | -37.0%#2 | — |
| ELAB | $38M#1 | — | 2.3x#9 | 64.2x#8 | — | -24.0%#6 | -1304.4%#8 | -46.3%#5 | — | — | — | — |
| CELU | $37M#2 | — | — | 1.4x#3 | -51.0%#6 | -58.4%#9 | -230.9%#3 | — | -398.1%#6 | — | — | — |
| CRVO | $37M#3 | 0.0x#1 | 1.6x#8 | 9.2x#6 | -58.9%#7 | -65.6%#11 | -706.2%#6 | -117.5%#10 | -5165.9%#7 | — | — | — |
| CNTX | $34M#4 | — | 0.9x#6 | — | — | -35.2%#8 | — | -94.6%#7 | — | — | — | — |
| LITS | $34M#5 | — | 0.6x#4 | — | -100.0%#9 | -189.7%#13 | — | -28.1%#4 | — | — | -62.4%#7 | — |
| FLNA | $33M#6 | — | 0.5x#2 | 0.8x#2 | 277.6%#1 | -273.7%#14 | -232.0%#4 | -133.5%#12 | — | — | -67.5%#9 | — |
| RMTI | $32M#7 | 267.0x#3 | 0.9x#7 | 0.5x#1 | -31.8%#5 | -1007.1%#16 | -6.8%#1 | -15.1%#3 | -14.0%#3 | 4#2 | — | — |
| CPHI | $31M#9 | — | 0.9x#5 | 7.5x#5 | -8.5%#4 | 32.7%#4 | -78.2%#2 | -8.8%#2 | -7.7%#1 | 5#1 | -61.2%#6 | — |
| KYNB | $31M#10 | 0.2x#2 | — | 4.8x#4 | -78.3%#8 | 485.6%#1 | -712.7%#7 | — | — | — | -37.9%#3 | — |
| RNAZ | $31M#11 | — | — | — | — | -106.9%#12 | — | — | — | — | -83.9%#10 | — |
| MIRA | $30M#12 | — | 3.7x#11 | — | — | -33.0%#7 | — | -127.9%#11 | — | — | -45.1%#5 | — |
| HEPA | $29M#13 | — | 22.4x#13 | — | — | 37.3%#3 | — | -647.5%#13 | — | — | -17.6%#1 | — |
| APUS | $3M#16 | — | 0.0x#1 | — | — | -331.7%#15 | — | -5.6%#1 | -11.2%#2 | — | -90.1%#11 | — |
| ABVC | $28M#14 | — | 2.7x#10 | 93.2x#9 | 0.0%#2 | -61.3%#10 | -2416.0%#9 | -76.9%#6 | -68.5%#4 | — | -63.6%#8 | — |
| IGC | $28M#15 | — | 4.5x#12 | 21.7x#7 | -5.5%#3 | 45.2%#2 | -585.8%#5 | -116.1%#8 | -125.5%#5 | 3#3 | -38.4%#4 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议